文献速递糖尿病

治疗口腔疾病对预防血管疾病的影响:2型糖尿病患者牙周治疗的模型成本效果分析

Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-Based Cost-effectiveness Analysis of Periodontal Treatment Among Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2019-12-27

基于美国人群的随机微模拟模型,评估扩大牙周治疗覆盖对2型糖尿病合并牙周炎患者的终生成本和健康收益。结果显示可减少34.1%的牙齿脱落及20.5%、17.7%、18.4%的肾病、神经病变和视网膜病变,人均净节省5904美元并增加0.6个质量调整生命年。

要点

  • 扩大牙周治疗覆盖预期减少34.1%牙齿脱落(95%CI -39.9, -26.5)。
  • 肾病、神经病变、视网膜病变分别减少20.5%、17.7%、18.4%。
  • 人均净节省5904美元(95%CI -6,039, -5,769),增加0.6个QALY。

核心结论

  • 对2型糖尿病合并牙周炎患者提供非手术牙周治疗,预期通过改善血糖控制显著减少牙齿脱落和2型糖尿病相关微血管疾病。
  • 鼓励口腔健康状况差的2型糖尿病患者接受牙周治疗可改善健康结局,且仍具有成本节约或成本效果。

研究设计与样本

  • 采用口腔健康状况、2型糖尿病、2型糖尿病相关微血管疾病和心血管疾病的随机微模拟模型进行成本效果分析,估算终生成本和健康收益。
  • 模型参数来自具有全国代表性的美国国家健康与营养调查(NHANES)(2009-2014)以及2型糖尿病患者牙周治疗的随机试验。

主要发现

  • 在2型糖尿病合并牙周炎患者中扩大牙周治疗覆盖,预期减少牙齿脱落34.1%(95%CI -39.9, -26.5)。
  • 预期减少微血管疾病:肾病20.5%(95%CI -31.2, -9.1)、神经病变17.7%(95%CI -32.7, -4.7)、视网膜病变18.4%(95%CI -34.5, -3.5)。
  • 从医疗保健角度,向目标人群提供牙周治疗可节省成本,总净节省5904美元(95%CI -6,039, -5,769),人均估计增加0.6个质量调整生命年(95%CI 0.5, 0.6)。

临床怎么用

  • 作者认为,鼓励口腔健康状况差的2型糖尿病患者接受牙周治疗可改善健康结局,且仍具有成本节约或成本效果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Previous randomized trials found that treating periodontitis improved glycemic control in patients with type 2 diabetes (T2D), thus lowering the risks of developing T2D-related microvascular diseases and cardiovascular disease (CVD). Some payers in the U.S. have started covering nonsurgical periodontal treatment for those with chronic conditions, such as diabetes. We sought to identify the cost-effectiveness of expanding periodontal treatment coverage among patients with T2D. RESEARCH DESIGN AND METHODS: A cost-effectiveness analysis was conducted to estimate lifetime costs and health gains using a stochastic microsimulation model of oral health conditions, T2D, T2D-related microvascular diseases, and CVD of the U.S. POPULATION: Model parameters were obtained from the nationally representative National Health and Nutrition Examination Survey (NHANES) (2009-2014) and randomized trials of periodontal treatment among patients with T2D. RESULTS: Expanding periodontal treatment coverage among patients with T2D and periodontitis would be expected to avert tooth loss by 34.1% (95% CI -39.9, -26.5) and microvascular diseases by 20.5% (95% CI -31.2, -9.1), 17.7% (95% CI -32.7, -4.7), and 18.4% (95% CI -34.5, -3.5) for nephropathy, neuropathy, and retinopathy, respectively. Providing periodontal treatment to the target population would be cost saving from a health care perspective at a total net savings of $5,904 (95% CI -6,039, -5,769) with an estimated gain of 0.6 quality-adjusted life years per capita (95% CI 0.5, 0.6). CONCLUSIONS: Providing nonsurgical periodontal treatment to patients with T2D and periodontitis would be expected to significantly reduce tooth loss and T2D-related microvascular diseases via improved glycemic control. Encouraging patients with T2D and poor oral health conditions to receive periodontal treatment would improve health outcomes and still be cost saving or cost-effective.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Choi SE, Sima C, Pandya A, et al. Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-Based Cost-effectiveness Analysis of Periodontal Treatment Among Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 31882408. doi:10.2337/dc19-1201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。